The succinate prodrug NV354 prevents brain lesions and late-stage motor dysfunction in mitochondrial complex I deficiency
Meagan J. McManus(Children's Hospital of Philadelphia), Todd J. Kilbaugh(Children's Hospital of Philadelphia), Johannes K. Ehinger(Lund University), Laura Sánchez-Benito(Universitat Autònoma de Barcelona), Abhay Ranganathan, Albert Quintana(Universitat Autònoma de Barcelona), Irene M. Yee(Lund University), Cesar Alves(Boston Children's Hospital), Sarah Piel(Düsseldorf University Hospital), Steven J. Moss, Nina Duncan(Children's Hospital of Philadelphia), Neha Kohli(Children's Hospital of Philadelphia), Eskil Elmér(Medicon Village), Elisenda Sanz(Universitat Autònoma de Barcelona), Malkah Sheldon(Children's Hospital of Philadelphia), Michael Karlsson(Lund University), Douglas C. Wallace(Children's Hospital of Philadelphia), Walter J. McHugh(Children's Hospital of Philadelphia), Yi Zhu(Children's Hospital of Philadelphia), Lee Webster(Isomerase Therapeutics (United Kingdom)), Patricia Prada-Dacasa(Universitat Autònoma de Barcelona), Alvar Grönberg(Medicon Village), Jennie Meng(Children's Hospital of Philadelphia), Lozen Robinson(Children's Hospital of Philadelphia), Magnus J. Hansson(Medicon Village)
Cited by 0
Related Papers
Agouti-related peptide neural circuits mediate adaptive behaviors in the starved state
|Nature Neuroscience|2016|311
Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
|Seminars in Oncology|2010|170
Cell-permeable succinate prodrugs bypass mitochondrial complex I deficiency
|Nature Communications|2016|153